Quidel Corporation (QDEL) CEO Douglas C. Bryant Sells 12,000 Shares

Quidel Corporation (NASDAQ:QDEL) CEO Douglas C. Bryant sold 12,000 shares of the stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $42.29, for a total transaction of $507,480.00. Following the completion of the sale, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $12,538,688.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Quidel Corporation (NASDAQ QDEL) opened at 40.95 on Wednesday. The firm’s market cap is $1.37 billion. The company has a 50-day moving average of $41.96 and a 200 day moving average of $32.26. Quidel Corporation has a 52-week low of $18.25 and a 52-week high of $45.55.

TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/01/quidel-corporation-qdel-ceo-douglas-c-bryant-sells-12000-shares.html.

Several research firms recently weighed in on QDEL. Canaccord Genuity reiterated a “buy” rating and issued a $48.00 target price on shares of Quidel Corporation in a research note on Wednesday, October 25th. Barclays PLC increased their price target on shares of Quidel Corporation from $36.00 to $39.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. BidaskClub lowered shares of Quidel Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Piper Jaffray Companies raised shares of Quidel Corporation from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $35.00 to $50.00 in a research report on Tuesday, September 19th. Finally, Raymond James Financial, Inc. increased their price target on shares of Quidel Corporation from $36.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Quidel Corporation currently has an average rating of “Buy” and a consensus price target of $48.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in Quidel Corporation by 4.0% in the 2nd quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock valued at $197,000 after purchasing an additional 278 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Quidel Corporation by 1.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,831 shares of the company’s stock valued at $593,000 after purchasing an additional 333 shares during the period. AHL Partners LLP boosted its holdings in Quidel Corporation by 4.0% in the 2nd quarter. AHL Partners LLP now owns 18,666 shares of the company’s stock valued at $507,000 after purchasing an additional 718 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in Quidel Corporation by 1.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 99,227 shares of the company’s stock valued at $2,693,000 after purchasing an additional 1,062 shares during the period. Finally, Acrospire Investment Management LLC boosted its holdings in Quidel Corporation by 42.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock valued at $100,000 after purchasing an additional 1,091 shares during the period. 86.92% of the stock is owned by hedge funds and other institutional investors.

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel Corporation (NASDAQ:QDEL)

What are top analysts saying about Quidel Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quidel Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit